Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | SCN1A | P35498 | 1/20 | 0.55 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.55 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13312439 | 0.89 | ALDH1A1 (0.62) | MAPTHTTHPGDALOX12MAPK1 | |
| SCHEMBL16215153 | 0.86 | KDM1A (0.58) | MAPTHTTHPGDALOX12MAPK1 | |
| SCHEMBL5346635 | 0.85 | ALDH1A1 (0.74) | MAPTHTTHPGDMEN1KMT2A | |
| SCHEMBL679125 | 0.83 | TSHR (0.69) | MAPTHPGDMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1689206 | 0.83 | EPHX2 (0.68) | MAPTHTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10016247 | 0.82 | MEN1 (0.55) | MAPTHTTHPGDMAPK1MEN1 | |
| SCHEMBL13841452 | 0.82 | POLB (0.74) | HTTHPGDMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL7130171 | 0.82 | TSHR (0.67) | MAPTHPGDMAPK1ALDH1A1RAB9A | |
| SCHEMBL9158253 | 0.82 | MAPT (0.53) | MAPTHTTHPGDALOX12MAPK1 | |
| SCHEMBL9674670 | 0.82 | MAPT (0.55) | MAPTHTTHPGDALOX12MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116969904-A | Compounds useful as autophagy modulators, methods of preparation and uses thereof | 微境生物医药科技(上海)有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-3632903-B1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| CN-111148740-B | Compounds useful as autophagy modulators, methods of preparation and uses thereof | 微境生物医药科技(上海)有限公司 | 2023-08-25 | — | — | CN | disclosed |
| WO-2023107863-A1 | HETEROCYCLIC COMPOUNDS AS KIT KINASE INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11319303-B2 | Compound used as autophagy regulator, and preparation method therefor and uses thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-11319303-B2 | Compound used as autophagy regulator, and preparation method therefor and uses thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20200190066-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-06-18 | — | — | US | disclosed |
| US-20200190066-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-06-18 | — | — | US | disclosed |
| CN-111148740-A | Compounds useful as autophagy modulators and methods of making and using the same | 微境生物医药科技(上海)有限公司 | 2020-05-12 | — | — | CN | disclosed |
| EP-3632903-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2020-04-08 | — | — | EP | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| EP-1399146-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARM INC (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2005049564-A1 | AMIDE DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20050107355-A1 | Amide derivatives and methods of their use | CUBIST PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| EP-1511732-A1 | PROCESS FOR THE MANUFACTURE OF QUINOLINE DERIVATIVES | Active Biotech AB (SE) | 2005-03-09 | — | — | EP | disclosed |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | AXYS PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| EP-1399146-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003106424-A1 | PROCESS FOR THE MANUFACTURE OF QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2003-12-24 | — | — | WO | disclosed |
| WO-2002098406-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319303-B2 | Compound used as autophagy regulator, and preparation method therefor and uses thereof | ATG7, SQSTM1, BECN1 | MAPT 763/4885HTT 1231/4885HPGD 3647/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | MAPT 2430/4885HTT 572/4885HPGD 2268/4885 |
| US-20200190066-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | ATG7, SQSTM1, BECN1 | MAPT 763/4885HTT 1231/4885HPGD 3647/4885 |
| US-20050107355-A1 | Amide derivatives and methods of their use | HRH2, SLC10A2, ALPI | MAPT 3008/4885HTT 3993/4885HPGD 63/4885 |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | CAPNS1, CTSS, CTSV | MAPT 3893/4885HTT 1514/4885HPGD 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.